Forward P/S Multiple: Zynex (ZYXI)

Zynex, Inc. - graphic logo of issuer ZYXI

Zynex, Inc. (ZYXI) is protected by patents and FDA approval, which creates high barriers to entry for new players. This GURU.Markets forward price-to-sales chart illustrates a local trend where the value of 0.00 characterizes this level. The business relies on the closed-loop NexWave B2C cycle with high patient switching costs, while lifetime sales of electrostimulation consumables serve as a steady cash generator.

zynex.com - ZYXI Market Cap to Projected Revenue (period 07/04/2022 - 01/03/2026)

Summary analytical data breakdowns for Zynex, Inc. (ZYXI)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:ZYXI (Zynex Inc)
Product sample of Zynex Corp

Zynex, Inc. (ZYXI) leverages electrotherapy automation and predictive monitoring to scale revenue by reducing the burden on medical personnel. By analyzing the projected P/S trend, investors assess the market value of the stock relative to expected annual sales volume, which helps determine the fairness of the asset's valuation and the risk of a "value trap" amid inflationary pressure on consumer demand.

Who Zynex, Inc. competes with

Price-to-Projected Revenue Ratio Dexcom CGM DXCM|Penumbra Corp (PEN) - Market Cap to Future Revenue Ratio|Novanta Inc - Forward P/S Multiple|HAE (Haemonetics Corporation) - Market Cap to Projected Revenue|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED Inc.) - Forward P/S Multiple|Pulse Corp (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward P/S Multiple picardmedical.com (PMI)|Forward P/S Multiple SRDX (surmodics.com)|Forward P/S Multiple Senseonics Holdings, Inc. SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (Sanuwave Health Inc) - Forward Price-to-Revenue Multiple|Projected Price to Revenue Outset Medical OM|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio LENSAR Inc. LNSR|Price-to-Projected Revenue Ratio AVITA Medical Inc. (RCEL)|Profound Medical Corporation (PROF) - Projected Price to Revenue|Baird Medical Investment Holdings - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP Medical EDAP|Apyx Medical Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical ICCM|Pulmonx (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue TELA (TELA Bio Corp)|Price-to-Projected Revenue Ratio cytosorbents.com|Forward Price-to-Revenue Multiple Sensus Healthcare, Inc. (SRTS)|Forward P/S Multiple ECOR|RBOT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio inspira-technologies.com IINN|Price to Expected Revenue Ratio ICU (SeaStar Medical Holding Corp.)|IRIX: Forward Price-to-Revenue Multiple|ibs.inc - Price to Expected Revenue Ratio|XAIR: Forward P/S Multiple|Future Price to Revenue PFSA (Profusa Inc.)|Forward Price-to-Revenue Multiple SSKN|Price-to-Projected Revenue Ratio GCTK|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|Venus Concept - Market Cap to Projected Revenue|Forward P/S Multiple NUWE (Nuwellis Corp)|Forward Price to Sales AEMD|ASXC - Price-to-Projected Revenue Ratio|Projected Price to Revenue Avinger, Inc (AVGR)|BSGM: Forward P/S Multiple|Cutera (CUTR) - Forward P/S Multiple|KNW (Know Labs) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Inari Medical (NARI)|Price-to-Projected Revenue Ratio nevro.com (NVRO)|RSLS (ReShape Lifesciences, Inc.) - Forward Price to Sales|Forward P/S Multiple SILK (Silk Road Medical)